About Honz Pharmaceutical Co.Ltd(300086)
Assurance report on annual deposit and actual use of raised funds
Zhonghuan zhuanzi [2022] No. 1710025 Honz Pharmaceutical Co.Ltd(300086) all shareholders:
We are entrusted to verify the attached special report on the deposit and use of raised funds of Honz Pharmaceutical Co.Ltd(300086) (hereinafter referred to as ” Honz Pharmaceutical Co.Ltd(300086) “) as of December 31, 2021.
In accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies issued by the CSRC and the guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on the gem issued by the Shenzhen Stock Exchange, the special report on the deposit and use of raised funds is prepared to provide true, legal and complete physical evidence The responsibility of Honz Pharmaceutical Co.Ltd(300086) board of directors lies with the original written materials, duplicate materials, oral testimony and other evidences we deem necessary. Our responsibility is to give assurance opinions on the special report on the deposit and use of raised funds on the basis of the implementation of assurance work.
We have carried out the assurance work in accordance with the provisions of other assurance business standards for Chinese certified public accountants No. 3101 – assurance business other than audit or review of historical financial information, which requires us to abide by the code of professional ethics for Chinese certified public accountants, plan and carry out the verification work, so as to obtain reasonable assurance about whether there is no material misstatement in the special report on the deposit and use of raised funds. In the process of performing the assurance work, we have implemented the necessary procedures such as checking the accounting records and recalculating the amount of relevant items. We believe that our assurance work provides a reasonable basis for expressing opinions.
We believe that Honz Pharmaceutical Co.Ltd(300086) as of December 31, 2021, the special report on the deposit and use of raised funds has been prepared in accordance with the relevant provisions of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies and the guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM issued by the CSRC, It truthfully reflects the annual deposit and actual use of the raised funds of Honz Pharmaceutical Co.Ltd(300086) up to December 31, 2021 in all major aspects. This assurance report is only used for the purpose of disclosure of 3 Ning Xia Yin Xing Energy Co.Ltd(000862) 021 annual report and shall not be used for any other purpose.
Zhongshen Zhonghuan Certified Public Accountants (special general partnership) Chinese certified public accountant:
(project partner):
Li Hui, Chinese certified public accountant:
Jiang Wenqing, Wuhan, China, April 6, 2002
Honz Pharmaceutical Co.Ltd(300086)
Special report on the deposit and use of raised funds in 2021
According to the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (CSRC announcement [2012] No. 44) issued by the CSRC and the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange issued by the Shenzhen Stock Exchange The board of directors of Honz Pharmaceutical Co.Ltd(300086) (hereinafter referred to as “the company” or “the company”) prepared a special report on the annual deposit and actual use of raised funds as of December 31, 2021.
1、 Basic information of raised funds
(I) actual time of funds raised
With the approval of zjxk [2010] No. 549 document of China Securities Regulatory Commission, Honz Pharmaceutical Co.Ltd(300086) on May 13, 2010, publicly issued 25 million RMB ordinary shares to the public, with a par value of RMB 1 per share and an issue price of RMB 60. The total amount of funds raised was RMB 15000000000. After deducting the underwriting Commission, issuance handling fee, lawyer’s fee and other issuance expenses of securities companies, the total amount was RMB 5120230000, The net amount of funds actually raised is RMB 144879770000. The above funds were fully paid on May 18, 2010 and verified by the capital verification report “zsiyyz [2010] No. 01020003” issued by ZHONGSHEN International Certified Public Accountants Co., Ltd.
(II) amount used in previous years, amount used in current year and current balance
Time and amount (yuan)
As of December 31, 2020, the balance of raised funds was 7144624737 plus: interest income of the current year was 422205971 minus: amount used in the current year was 286466062; as of December 31, 2021, the balance of raised funds was 7280364646
2、 Management of raised funds
(I) formulation and implementation of raised funds management system
The company has formulated the raised funds management system in accordance with the requirements of laws and regulations such as the measures for the administration of securities issuance by listed companies, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, and the guidelines for the standardized operation of GEM listed companies of Shenzhen Stock Exchange, The company adopts a special account storage system for the raised funds.
(II) signing of special account for raised funds
The company signed the tripartite supervision agreement on raised funds with Haitong Securities Company Limited(600837) and Haikou Branch of Shenzhen Development Bank Co., Ltd. (later renamed Ping An Bank Co.Ltd(000001) Haikou Branch), Industrial And Commercial Bank Of China Limited(601398) Haikou Xiuying sub branch and Haikou Rural Commercial Bank Co., Ltd. on May 28, 2010, June 1, 2010 and October 15, 2012 respectively.
On December 31, 2015, the company transferred the special fund-raising account from Industrial And Commercial Bank Of China Limited(601398) Haikou Xiuying sub branch to Bank Of Communications Co.Ltd(601328) Haikou Nanhai sub branch, cancelled the special fund-raising account of Industrial And Commercial Bank Of China Limited(601398) Haikou Xiuying sub branch, and signed a tripartite supervision agreement on fund-raising with Haitong Securities Company Limited(600837) and Bank Of Communications Co.Ltd(601328) Haikou Nanhai sub branch.
On November 27, 2013, the company signed the four party supervision agreement on raised funds with the wholly-owned subsidiary Hainan Kangzhi Biotechnology Co., Ltd. (formerly Hainan Kangzhi Pharmaceutical Marketing Co., Ltd., renamed on September 30, 2019, hereinafter referred to as “Kangzhi biotechnology”), Haitong Securities Company Limited(600837) and Industrial And Commercial Bank Of China Limited(601398) Haikou Xiuying sub branch; On December 31, 2013, the supplementary agreement to the four party supervision agreement on raised funds was signed.
On December 31, 2015, the company signed the four party supervision agreement on raised funds with Kangzhi biology, Haitong Securities Company Limited(600837) and Bank Of Communications Co.Ltd(601328) Haikou Nanhai sub branch, transferring the special account for raised funds from Industrial And Commercial Bank Of China Limited(601398) to Bank Of Communications Co.Ltd(601328) Haikou Nanhai sub branch, and canceling the special account for raised funds of Industrial And Commercial Bank Of China Limited(601398) Haikou Xiuying sub branch.
On March 30, 2015, the company signed the four party supervision agreement on raised funds with its wholly-owned subsidiaries Guangdong Kangda Pharmaceutical Co., Ltd. (hereinafter referred to as “Kangda pharmaceutical”), Haitong Securities Company Limited(600837) and Liede Avenue sub branch of Guangzhou Branch of Guangdong Development Bank Co., Ltd.
On July 20, 2018, the company, Kangda pharmaceutical, Haitong Securities Company Limited(600837) and Guangzhou Branch Liede Avenue sub branch of Guangdong Development Bank Co., Ltd. signed the four party supervision agreement on raised funds (special account for super raised funds of hand, foot and mouth disease project). On November 21, 2012, the company signed the four party supervision agreement on raising funds with the holding subsidiaries Beijing Shunxin Xiangyun Pharmaceutical Co., Ltd. (hereinafter referred to as “Xiangyun pharmaceutical”), Haitong Securities Company Limited(600837) and Bank Of China Limited(601988) Beijing Shunyi Auto City sub branch.
On December 31, 2015, the company signed the four party supervision agreement on raised funds with Xiangyun pharmaceutical, Haitong Securities Company Limited(600837) and Bank Of Communications Co.Ltd(601328) Beijing Shunyi sub branch, transferred the special account for raised funds from Bank Of China Limited(601988) Beijing Shunyi Auto City sub branch to Bank Of Communications Co.Ltd(601328) Beijing Shunyi sub branch, and transferred all the remaining raised funds to the new raised funds account within the current month, and cancelled the original raised funds account.
On July 10, 2017, the wholly-owned subsidiary Zhongshan Hongshi Health Technology Co., Ltd. (hereinafter referred to as “Zhongshan Hongshi”), Haitong Securities Company Limited(600837) and Liede Avenue sub branch of Guangzhou Branch of Guangdong Development Bank Co., Ltd. signed the tripartite supervision agreement on the storage of special account for raised funds.
The contents of the above three-party or four-party regulatory agreements are drafted with reference to the model of Shenzhen Stock Exchange, and there is no significant difference. (III) storage of raised funds in special account
As of December 31, 2021, the balance of the special account for the deposit of raised funds is as follows:
Company name deposit bank account balance (yuan) remarks
Ping An Bank Co.Ltd(000001) Haikou Haidian sub branch 11004088765607189145484 current account
110040887656020.00 periodic
Honz Pharmaceutical Co.Ltd(300086) share demand
Ltd. Bank Of Communications Co.Ltd(601328) Haikou Nanhai sub branch 4616023030188 Norinco International Cooperation Ltd(000065) 14370751813
4616023030180100843509122.44 current account
Haikou rural commercial bank business department 10070987 China Vanke Co.Ltd(000002) 3811663.88 current account
Hainan Kangzhi biology 4616023030188 Tunghsu Azure Renewable Energy Co.Ltd(000040) 6273.65 current
Technology Co., Ltd. Bank Of Communications Co.Ltd(601328) Haikou Nanhai sub branch current account
4616023030188 North Huajin Chemical Industries Co.Ltd(000059) 55 25,570556.06
Guangdong Kangda pharmaceutical Guangdong Development Bank Guangzhou Branch Liede Avenue sub branch 12130151101 Shenzhen Wongtee International Enterprise Co.Ltd(000056) 378395853 current account
Ltd. Guangzhou Branch Liede Avenue sub branch of Guangdong Development Bank 9550880052310043454266178 current account
Beijing Shunxin Xiangyun 11006116201801020051223907971 current account
Pharmaceutical Co., Ltd. Bank Of Communications Co.Ltd(601328) Beijing Shunyi sub branch
Company 11006116201801 New Hua Du Supercenter Co.Ltd(002264) 5204.84 current account
Zhongshan Hongshi health Guangfa Bank Guangzhou Branch Liede Avenue sub branch current account
Technology Co., Ltd. 955
